New Australian venture to develop microRNA therapeutics for cancer
This article was originally published in Scrip
A new Australian venture company, MiReven, is being set up based on basic research conducted at the Western Australian Institute for Medical Research (WAIMR) into the anticancer effects of microRNA-7 (miR-7).
You may also be interested in...
Japanese ophthalmic specialist picks up young private US firm and gains a small but broad set of marketed products.
Cancer deals involving Junshi/Wigen, Allist/Octimet, Yufan/Abound, Takeda/Presage, Daiichi Sankyo/AnHeart, LegoChem/Harbour Biomed, plus a stem cell partnership and a lysosomal storage disorder agreement.
Japan coordinates initiative to improve regional early-stage development of novel cancer therapies, which will work both with the industry and independently to improve access.